Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world

被引：0
|
作者：
Sugisaka, J. [1 ]
Sugawara, S. [1 ]
Toi, Y. [1 ]
Ogasawara, T. [1 ]
Aso, M. [1 ]
Tsurumi, K. [1 ]
Ono, K. [1 ]
Shimizu, H. [1 ]
Domeki, Y. [1 ]
Aiba, T. [1 ]
Kawana, S. [1 ]
Saito, R. [1 ]
Terayama, K. [1 ]
Kawashima, Y. [1 ]
Nakamura, A. [1 ]
Yamanda, S. [1 ]
Kimura, Y. [1 ]
Honda, Y. [1 ]
机构：
[1] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
336P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Leiby, Melanie A.
    Lubiniecki, Gregory M.
    Shentu, Yue
    Rangwala, Reshma
    Brahmer, Julie R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1823 - 1833
  • [2] Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?
    Gridelli, Cesare
    Sgambato, Assunta
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [3] A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non-small cell lung cancer
    Isono, Taisuke
    Kagiyama, Naho
    Shibata, Shun
    Nakajima, Hitomi
    Matsui, Yuma
    Takano, Kenji
    Nishida, Takashi
    Hosoda, Chiaki
    Kawate, Eriko
    Kobayashi, Yoichi
    Ishiguro, Takashi
    Takaku, Yotaro
    Kurashima, Kazuyoshi
    Yanagisawa, Tsutomu
    Takayanagi, Noboru
    THORACIC CANCER, 2021, 12 (09) : 1387 - 1397
  • [4] REAL WORLD OUTCOMES OF FIRST LINE PEMBROLIZUMAB MONOTHERAPY FOR ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S253 - S253
  • [5] Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer
    Zhou, Yixin
    Zhang, Yaqiong
    Guo, Guifang
    Cai, Xiuyu
    Yu, Hui
    Cai, Yanyu
    Zhang, Bei
    Hong, Shaodong
    Zhang, Li
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 10 (01): : 107 - 115
  • [6] Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC)
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Burke, Thomas
    CANCER RESEARCH, 2019, 79 (13)
  • [7] Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
    Mienko, Fiona
    Halmos, Balazs
    Cheng, Haiying
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (12)
  • [8] Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
    Thu Oanh Dang
    Ogunniyi, Adebayo
    Barbee, Meagan S.
    Drilon, Alexander
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (01) : 13 - 20
  • [9] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
    Hui, R.
    Garon, E. B.
    Goldman, J. W.
    Leighl, N. B.
    Hellmann, M. D.
    Patnaik, A.
    Gandhi, L.
    Eder, J. P.
    Ahn, M-J
    Horn, L.
    Felip, E.
    Carcereny, E.
    Rangwala, R.
    Lubiniecki, G. M.
    Zhang, J.
    Emancipator, K.
    Roach, C.
    Rizvi, N. A.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 874 - 881
  • [10] THE PROMISING ROLE OF PEMBROLIZUMAB IN THE MANAGEMENT OF PATIENTS WITH PD-L1-POSITIVE NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW
    Gadi, H. R.
    Gollala, M. K.
    Kethireddy, K.
    Ganta, M. R.
    Kankanampati, N.
    VALUE IN HEALTH, 2018, 21 : S17 - S17
12345